Skip to content

Advertisement

You're viewing the new version of our site. Please leave us feedback.

Learn more

BMC Proceedings

Open Access

Evaluation of potential antimicrobial chlorhexidine digluconate microencapsulated in model experimental dental biofilm

  • Giselle Medeiros da Costa One1,
  • Allan de Jesus dos Reis Albuquerque1,
  • Daniela Correia Cavalcante Souza1 and
  • Fabio Correia Sampaio1
BMC Proceedings20148(Suppl 4):P86

https://doi.org/10.1186/1753-6561-8-S4-P86

Published: 1 October 2014

Background

The formation of biofilm on the tooth surface is a result of the process of colonization of cariogenic bacteria, especially Streptococcus mutans, the main responsible for cariogenic (acid production) of dental biofilms [1]. The removal and chemical control of dental biofilm with chlorhexidine digluconate 0.12% (CLX) has been the most effective antimicrobial agent of choice clinic. However, despite its indisputable efficacy, no side effects such as darkening of the teeth, tongue and restorations, burning mouth and changes in taste. The formation of inclusion compounds CLX for the controlled release of the compound in a lower concentration could be a viable strategy to reduce these side effects without diminishing the therapeutic efficacy of the product [2, 3]. Against this background, this study aimed to prepare nanocapsules CLX (processing aid) (1.2%) in model spray drying using modified starch as the encapsulating agent, tested in biofilm model using bovine teeth.

Methods

The microbiological evaluation of in vitro antimicrobial activity of different formulations was made against S. mutans strain UA159 grown in artificial saliva, a model of biofilm produced in the flow cell. The biofilm on the teeth was exposed to nano-CLX, CLX Periogard ® and standard laboratory for 2 minutes. Cell viability was measured by fluorescence LiveDeadBactLightTM Kit with dyes Syto ® 9 and Propidium Iodide.

Results

The results showed equivalence between efficiency and CLX laboratory Periogard ®, featuring both 0% percentage of S. mutans after treatment. The CLX nanocoated (1.2%) showed significant efficiency at 90% cell death indicating controlled release of the drug. The model CLX nanocoated by spray drying, and modified starch as encapsulating agents when tested in a model of biofilm using bovine teeth showed good response when used as antimicrobial.

Conclusions

The molecular nature of chlorhexidine ensures its effectiveness in combating bacterial biofilms, and such activity is in fact already enshrined. However, the alternative formulation nanocapsulada allows an effective control of its release, ensuring control of the main process cariogenic bacteria, thereby reducing their undesirable aesthetic point of view, representing new alternative for the application and release of a single antimicrobial without the immediate need for new drugs.

Declarations

Acknowledgements

Laboratory of Oral Biology.

Authors’ Affiliations

(1)
Federal University of Paraiba

References

  1. P D: Dental plaque as a microbial biofilm Caries Res. 2004, 38 (3): 204-211.Google Scholar
  2. Cortés ME, Sinisterra RD, Ávila-Campos MJ, Tortamano N, Rocha RG: The chlorhexidine:beta-ciclodextrin inclusion compound: preparation, characterization and microbiological evaluation. J Inclusion Phen Macrocyclic Chem. 2001, 40: 297-302.View ArticleGoogle Scholar
  3. Smith AW: Biofilms and antibiotic therapy: Is there a role for combating bacterial resistance by the use of novel drug delivery systems?. Advanced Drug Delivery Reviews. 2005, 57: 1539-50.View ArticlePubMedGoogle Scholar

Copyright

© Costa One et al.; licensee BioMed Central Ltd. 2014

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Advertisement